AC Immune stock jumps 20% on data for Parkinson's disease drug
AC Immune (NASDAQ:ACIU) stock shot up 20% Thursday after the company reported positive interim data from a Phase 2 study of ...
Science Daily1h
New model system for the development of potential active substances used in condensate modifying drugs
Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...
Epilepsy Society4h
Health minister responds to call for review of medicines supply chain
The Epilepsy Society was pleased to receive a reply from Health Minister, Karin Smyth in response to our letter calling for a top-to-toe review of the.
Psychology Today21h
My Parkinson's Year 5 Update
When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...
ITV Emmerdale Christmas storyline 'confirmed' ahead of character's sad exit
Emmerdale viewers have their first hints at a Christmas storyline on the ITV soap in new spoilers, amid the news one fan ...
Slow editing of protein blueprints leads to cell death, spliceosome study discovers
An international research team has uncovered a new mechanism crucial to the production of cellular proteins. When this ...
AC Immune’s Promising Trial Results for Parkinson’s Therapy
AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...
Medpage Today on MSN23h
Gabapentinoids Tied to Hip Fractures in Older Adults
Gabapentinoids -- pregabalin and gabapentin -- were tied to increased hip fracture risk in older adults. Gabapentinoids -- ...
pharmaphorum22h
Data backs AZ's Wilson disease drug, but with a question mark
Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.